Cancer cell lines with mutations that cause the constitutive activation of PI3K (or loss-of-function mutations in PTEN, which normally antagonizes PI3K) are fully refractory to the tumor growth-inhibitory effects of DR. This evidence concerns the gene PTEN and neoplasm.